FCGRT and myasthenia gravis: Against this background, recent advances have been made in developing novel therapeutics based on the molecular pathogenesis of MG, with particular attention to molecularly targeted therapies such as neonatal Fc receptor (FcRn) inhibitors and complement inhibitors.